Pharmaceutical News and Articles
Clinical Trial Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
FREMONT, Calif.--(BUSINESS WIRE)--Nov 2, 2009 - Zosano Pharma,
Inc., a privately held pharmaceutical company developing products
using a novel transdermal delivery technology, today announced that
the company will present two posters at the 2009...
Aranesp(R) (Darbepoetin Alfa) Did Not Reduce the Risk of
Mortality, Cardiovascular Morbidity, or End Stage Renal Disease
Results Show Increased Risk of Stroke Among Patients Treated to a
Hemoglobin of 13 g/dL
THOUSAND OAKS, Calif., Oct. 30...
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE:SGP)
today reported two data presentations supporting response guided
therapy with boceprevir combination therapy in patients with
chronic hepatitis C virus (HCV)...
- BENLYSTA (belimumab) 10 mg/kg plus standard of care met its
primary efficacy endpoint by achieving a statistically significant
improvement in patient response rate versus placebo plus standard
of care at Week 52 in BLISS-76 -
- Primary...
KENILWORTH, N.J., Nov 02, 2009
/PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation
(NYSE: SGP) today announced that its investigational sublingual
Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met
the primary...
QUÉBEC CITY, Nov. 2 /CNW Telbec/ - Æterna Zentaris
Inc. (TSX: AEZ; Nasdaq: AEZS) (the "Company"), a global
biopharmaceutical company focused on endocrine therapy and
oncology, today announced positive efficacy data from a Phase 2
study with...
BERKELEY HEIGHTS, NJ – October 29, 2009 - Genta
Incorporated (OTCBB: GETA) today announced top-line results from
AGENDA, the Company’s Phase 3 trial of Genasense®
(oblimersen sodium) Injection in patients with advanced
melanoma.
AGENDA is...
Phase 2b Data Presented at American Association for the Study of
Liver Diseases Meeting
LOUISVILLE, Colo., Nov. 2, 2009 - GlobeImmune Inc. will present
Phase 2b data today at the 60th Annual Meeting of the American
Association for the Study of...
LONDON, Nov. 2, 2009--Biotechnology company NovaBiotics, which
focuses on the design and development of novel peptide antifungal
and antibacterial therapeutics, confirms that the first patients
enrolled in its Novexatin® Phase IIa clinical trial...
- Canadian POWeR and REDIPEN(R) Programs presented at the
American Association for the Study of Liver Diseases Annual Meeting
-
KIRKLAND, QC, Nov. 2 /CNW/ - Results from two significant
Canadian studies underscore the growing scientific...
First HEPLISAV Chronic Kidney Disease Data to be Presented at
IDSA
BERKELEY, Calif.--(BUSINESS WIRE)--Oct 29, 2009 - Dynavax
Technologies Corporation (Nasdaq: DVAX) today announced the first
clinical data for HEPLISAVTM investigational...
Data Demonstrate Protective Effect and Durability of
Rifaximin for Maintenance of Remission of Hepatic
Encephalopathy
Data Demonstrate Rifaximin Significantly Improved Critical
Flicker Frequency and Time-Weighted CFF Correlated with...
Potential for Rapid and Prolonged Therapeutic Benefit in HCV
through Protein Silencing of NS3 Protease
BOSTON & WALTHAM, Mass.--(BUSINESS WIRE)--Nov 2, 2009 -
Avila Therapeutics™, Inc., a biotechnology company developing
novel covalent drugs...
– New Data Demonstrate Durable In Vivo Efficacy for
ALN-TTR –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 2, 2009 - Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it presented new...
Presentations at American Society of Nephrology Renal Week
2009 Characterize Binding, Immunogenicity Profile for
Hematide
PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Oct
30, 2009 - Affymax, Inc. (Nasdaq:AFFY) and Takeda...
Philadelphia, PA – October 30, 2009 – Patients who
acquire skin and soft tissue infections (SSTIs) in a hospital or
other healthcare setting may be more likely to receive
inappropriate antibiotic therapy at the beginning of their
treatment....
Study reports on persistence of benefits seen in the Diabetes
Prevention Program
BETHESDA, Md., Oct. 29, 2009-Intensive lifestyle changes aimed
at modest weight loss reduced the rate of developing type 2
diabetes by 34 percent compared with...
Preliminary Results Indicate that Florbetaben PET Imaging
Scans May Differentiate Patients with Probable Alzheimer's Disease
from Healthy Volunteers
BANGKOK, Oct. 30 /PRNewswire/ -- Bayer HealthCare presented
results from a global Phase II study...
CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ:IDIX) , a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment
of human viral diseases, today announced...
Presentations Highlight: - Potency against Contemporary S.
aureus strains, Including MRSA - Low Level Resistance Development
despite Decades of Use Outside the U.S. - PK-PD Underlying Novel
Oral Loading Dose Regimen to minimize future...
More...
